Alltranz Inc.

University of Kentucky Research Foundation

Zynerba Pharmaceuticals, Inc.

Buzzz Pharmaceuticals Limited

Other

University System of Maryland

Xillus, Inc.

Audra Lynn Stinchcomb

Miroslaw Jerzy Golinski

Dana Carmel Hammell

Stan Lee Banks

Jeffrey Lynn Howard

Jeffery Lynn Howard

Peter Anthony Crooks

Priyanka Ghosh

Josh Eldridge

Mohamed Omer Hamad

Buchi N Nalluri

Julian Van Erlach

Arlen L Olsen

Mark D Scott

Kyung Bo Kim

Jeffrey M Smith

Gerald E Bender

Denis P Donnelly

Roger D Whitmer

Bruce Jackson Hinds, Iii

Ragotham Reddy Pinninti

Laura B Smith

Kalpana S Paudel

James E Peterson

Gerald F Dudding

Peter W Swaan

Paul K Kiptoo

Guohua Li

Jeffry Lynn Howard

Dand Carmel Hammell

An abuse deterrent transdermal patch comprising a multilaminate. The multilaminate can comprise a first layer comprising an opioid analgesic compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable pressure sensitive adhesive. The multilaminate can further comprise a second layer comprising an opioid antagonist, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adhesive. In addition, the multilaminate can further comprise a barrier layer disposed between the first and second layers.

Abuse deterrent opioid/opioid-antagonist transdermal patch

The present invention relates to a transdermal patch comprising oxymorphone. The present invention also relates to processes for the preparation of the transdermal patches defined herein, as well as to the use of these patches for the treatment of pain.

Oxymorphone transdermal patch

Microneedles and their use as a physical skin permeation enhancement technique facilitate drug delivery across the skin in therapeutically relevant concentrations. Micropores created in the skin by MNs reseal because of normal healing processes of the skin, thus limiting the duration of the drug delivery window. Pore lifetime enhancement strategies can increase effectiveness of MNs as a drug delivery mechanism by prolonging the delivery window. Fluvastatin (FLU) was used to enhance pore lifetime by inhibiting the synthesis of cholesterol, a major component of the stratum corneum lipids. The skin recovered within a 30-45-min time period following the removal of occlusion, and there was no significant irritation observed due to the treatment compared to the control sites. Thus, it can be concluded that localized skin treatment with FLU can be used to extend micropore lifetime and deliver drugs for up to 7 days across MN-treated skin.

Extending and maintaining micropore viability of microneedle treated skin with lipid biosynthesis inhibitors for sustained drug delivery

Described herein are &#x394;-THC prodrugs, methods of making &#x394;-THC prodrugs, formulations comprising &#x394;-THC prodrugs and methods of using &#x394;-THC. One embodiment described herein relates to the transdermal administration of a &#x394;-THC prodrug for treating and preventing diseases and/or disorders.

Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same

The presently-disclosed subject matter includes compounds including a cyclooxygenase enzyme inhibitor moiety and a moiety derived from a drug of interest. In some embodiments, the drug of interest is an opioid. In some embodiments, the compound includes a diclofenac moiety and a naltrexone or naltrexol moiety. The compounds allow for enhanced delivery rates across skin.

Compounds including Cox inhibitor moiety and enhanced delivery of active drugs using same

Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.

Use of cannabidiol prodrugs in topical and transdermal administration with microneedles

The present invention is directed to novel codrugs comprising bupropion or hydroxybupropion and an opioid antagonist or an opioid agonist joined together by chemical bonding. The codrugs provide a significant increase in the transdermal flux across human skin, as compared to the basic opioid antagonist or opioid agonist.

Enhancing transdermal delivery of opioid antagonists and agonists using codrugs linked to bupropion or hydroxybupropion

Described herein are abuse-resistant multi-layer transdermal patches comprising opioids and opioid prodrugs having a barrier layer located between the layer containing opioid or opioid prodrug and a layer containing an opioid antagonist or opioid antagonist prodrug.

Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists

The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient. A first aspect of the invention provides a method for relieving symptoms associated with illness or associated with the treatment of illness in a mammalian subject, comprising the steps of selecting at least one cannabinoid from the group consisting of cannabinol, cannabidiol, nabilone, levonantradol, (&#x2212;)-HU-210, (+)-HU-210, 11-hydroxy-&#x394;-THC, &#x394;-THC-11-oic acid, CP 55,940, and R(+)-WIN 55,212-2, selecting at least one permeation enhancer from the group consisting of propylene glycol monolaurate, diethylene glycol monoethyl ether, an oleoyl macrogolglyceride, a caprylocaproyl macrogolglyceride, and an oleyl alcohol, and delivering the selected cannabinoid and permeation enhancer transdermally to treat an illness.

Transdermal delivery of cannabidiol

Described herein are opioid prodrugs, methods of making opioid prodrugs, formulations comprising opioid prodrugs, and methods of using opioid prodrugs. One embodiment described herein relates to the transdermal administration of a buprenorphine prodrug in an abuse-resistant formulation for treating and preventing diseases and/or disorders.

Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs

Described herein are cannabidiol prodrugs, methods of making cannabidiol prodrugs, formulations comprising cannabidiol prodrugs and methods of using cannabidiols. One embodiment described herein relates to the transdermal or topical administration of a cannabidiol prodrug for treating and preventing diseases and/or disorders.

Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same

Growing community of inventors

Lexington, KY, United States of America

Audra Lynn Stinchcomb